April 24, 2024
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
April 17, 2024
Alkermes to Report First Quarter Financial Results on May 1, 2024
April 09, 2024
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 a...
Hear from Bhaskar Rege, Ph.D., as he shares his perspective on the importance of elevating the patient voice this World Sleep Day and beyond.
In celebration of International Women's Day, we asked three senior female leaders at Alkermes to reflect on their career journeys and their efforts to inspire inclusion.
Blair Jackson shares his thoughts on Alkermes' past and future as a neuroscience company.
Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.